Yinkang-003

N/A

Report date: 2025/03/20 09:21:10

Base Information

Drug NameYinkang-003
Drug Alias Nameanti-CD20/CD3 program (Yinkang Biopharma)
ClassificationBiologics
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsB-lymphocyte antigen CD20 inhibitors
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYinkang Biopharma Inc.
China Registration ClassN/A

Develop Information

Active CompaniesYinkang Biopharma Inc.
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A